東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Engineering Better Treatments for Diabetes: From Next-Gen Insulin Drugs to Autonomous Insulin Delivery.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Engineering Better Treatments for Diabetes: From Next-Gen Insulin Drugs to Autonomous Insulin Delivery./
作者:	Maikawa, Caitlin L.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	364 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-05, Section: B.
Contained By:	Dissertations Abstracts International83-05B.
標題:	Biocompatibility. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28812953
ISBN:	9798494455253

Engineering Better Treatments for Diabetes: From Next-Gen Insulin Drugs to Autonomous Insulin Delivery.
Maikawa, Caitlin L.

Engineering Better Treatments for Diabetes: From Next-Gen Insulin Drugs to Autonomous Insulin Delivery. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 364 p.

Source: Dissertations Abstracts International, Volume: 83-05, Section: B.

Thesis (Ph.D.)--Stanford University, 2021.

This item must not be sold to any third party vendors.

Insulin was first isolated a century ago, yet commercial formulations of insulin and its analogues for hormone replacement therapy falls short of mimicking the endogenous glycemic control that occurs in non-diabetic individuals. Moreover, diabetes management is increasingly relying automated insulin delivery using closed-loop systems to improve glucose management and reduce patient burden. However improvements in insulin formulations, sensors, and algorithms are required to shift from hybrid systems to fully autonomous delivery. Insulin formulations that better mimic secretion from the beta-cells, by enabling more rapid insulin absorption kinetics and/or co-delivering complementary hormones (i.e. amylin), would improve diabetes management. However, formulation innovation is complicated by the poor stability of insulin monomers and amylin. During my time in the Appel lab, I have developed two polymeric excipient platforms (non-covalent PEGylation and amphiphilic copolymer excipients) that can be used to increase the stability of insulin in formulation. Using these designer excipients, I have developed three enhanced insulin formulations: (i) an ultrafast monomeric insulin lispro (ii) an insulin-amylin co-formulation and (iii) an ultra-stable insulin for improved global access. These three enhanced insulin formulations are promising candidates for improving glucose control and reducing burden for patients with diabetes. Beyond formulation engineering, through collaborations I have investigated the use of open-source algorithms in a full closed-loop setting as well as helped to develop a continuous real-time ELISA microfluidic device for continuous monitoring of insulin and glucose. Together, this collection of work describes the development of new technologies towards insulin delivery with the goal of improving glucose management in patients with diabetes.

ISBN: 9798494455253Subjects--Topical Terms:

656157
Biocompatibility.

Engineering Better Treatments for Diabetes: From Next-Gen Insulin Drugs to Autonomous Insulin Delivery.
LDR:03252nmm a2200481 4500 001 2347536
005 20220801062230.5
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798494455253
035 $a (MiAaPQ)AAI28812953
035 $a (MiAaPQ)STANFORDzj411yx1243
035 $a AAI28812953
040 $a MiAaPQ $c MiAaPQ
100 1 $a Maikawa, Caitlin L. $3 3686800
245 1 0 $a Engineering Better Treatments for Diabetes: From Next-Gen Insulin Drugs to Autonomous Insulin Delivery.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 364 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-05, Section: B.
500 $a Advisor: Appel, Eric;Cochran, Jennifer;Maahs, David.
502 $a Thesis (Ph.D.)--Stanford University, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Insulin was first isolated a century ago, yet commercial formulations of insulin and its analogues for hormone replacement therapy falls short of mimicking the endogenous glycemic control that occurs in non-diabetic individuals. Moreover, diabetes management is increasingly relying automated insulin delivery using closed-loop systems to improve glucose management and reduce patient burden. However improvements in insulin formulations, sensors, and algorithms are required to shift from hybrid systems to fully autonomous delivery. Insulin formulations that better mimic secretion from the beta-cells, by enabling more rapid insulin absorption kinetics and/or co-delivering complementary hormones (i.e. amylin), would improve diabetes management. However, formulation innovation is complicated by the poor stability of insulin monomers and amylin. During my time in the Appel lab, I have developed two polymeric excipient platforms (non-covalent PEGylation and amphiphilic copolymer excipients) that can be used to increase the stability of insulin in formulation. Using these designer excipients, I have developed three enhanced insulin formulations: (i) an ultrafast monomeric insulin lispro (ii) an insulin-amylin co-formulation and (iii) an ultra-stable insulin for improved global access. These three enhanced insulin formulations are promising candidates for improving glucose control and reducing burden for patients with diabetes. Beyond formulation engineering, through collaborations I have investigated the use of open-source algorithms in a full closed-loop setting as well as helped to develop a continuous real-time ELISA microfluidic device for continuous monitoring of insulin and glucose. Together, this collection of work describes the development of new technologies towards insulin delivery with the goal of improving glucose management in patients with diabetes.
590 $a School code: 0212.
650 4 $a Biocompatibility. $3 656157
650 4 $a Flow velocity. $3 3564851
650 4 $a Cytotoxicity. $3 3682273
650 4 $a Carbohydrates. $3 522687
650 4 $a Hypoglycemia. $3 1602849
650 4 $a Hogs. $3 3554056
650 4 $a Metabolism. $3 541349
650 4 $a Rodents. $3 3686801
650 4 $a Drug dosages. $3 3557732
650 4 $a Innovations. $3 754112
650 4 $a Patients. $3 1961957
650 4 $a Polymers. $3 535398
650 4 $a Mass spectrometry. $3 551172
650 4 $a Hormone replacement therapy. $3 3562671
650 4 $a Aging. $3 543123
650 4 $a Kinetics. $3 717752
650 4 $a Engineering. $3 586835
650 4 $a Algorithms. $3 536374
650 4 $a Libraries. $3 525303
650 4 $a Interfaces. $2 gtt $3 834756
650 4 $a Analytical chemistry. $3 3168300
650 4 $a Animal sciences. $3 3174829
650 4 $a Chemistry. $3 516420
650 4 $a Computer science. $3 523869
650 4 $a Endocrinology. $3 610914
650 4 $a Fluid mechanics. $3 528155
650 4 $a Gerontology. $3 533633
650 4 $a Library science. $3 539284
650 4 $a Mechanics. $3 525881
650 4 $a Medicine. $3 641104
650 4 $a Morphology. $3 591167
650 4 $a Physics. $3 516296
650 4 $a Polymer chemistry. $3 3173488
650 4 $a Therapy. $3 3343697
690 $a 0493
690 $a 0537
690 $a 0486
690 $a 0475
690 $a 0485
690 $a 0984
690 $a 0409
690 $a 0204
690 $a 0351
690 $a 0399
690 $a 0346
690 $a 0564
690 $a 0287
690 $a 0605
690 $a 0495
690 $a 0212
710 2 $a Stanford University. $3 754827
773 0 $t Dissertations Abstracts International $g 83-05B.
790 $a 0212
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28812953